Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
11 Julio 2023 - 12:30AM
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
|
Press Release |
|
Nicox: Half-year liquidity contract statement with Kepler
Cheuvreux |
July 11, 2023 – release at 7:30 am CET Sophia Antipolis,
France
Under the liquidity contract entered into
between Nicox and Kepler Cheuvreux, the following resources
appeared on the liquidity account on June 30, 2023:
- 304,567 shares
- € 10,640.56
- Number of executions on buy side on
semester: 128
- Number of executions on sell side
on semester: 111
- Traded volume on buy side on
semester: 74,584 shares for € 62,919.32
- Traded volume on sell side on
semester: 58,982 shares for € 51,368.57
As a reminder:
- The following resources appeared on
the last half year statement on December 31, 2022 on the liquidity
account:
- 288,965 shares
- € 22,074.60
- Number of executions on buy side on
semester: 274
- Number of executions on sell side
on semester: 195
- Traded volume on buy side on
semester: 155,703 shares for € 262,378.38
- Traded volume on sell side on
semester: 100,347 shares for € 178,155.02
- The following resources appeared on
the liquidity account when the activity started:
The implementation of this report is carried out in accordance
with AMF Decision N°2021-01 of June 22nd 2021 renewing the
implementation of liquidity contracts for shares as an accepted
market practice.
| |
Buy Side |
|
Sell Side |
| |
Number of
executions |
Number of
shares |
Traded volume in EUR |
|
Number of
executions |
Number of
shares |
Traded volume in EUR |
|
Total |
128 |
74 584 |
62 919.32 |
|
128 |
74 584 |
62 919.32 |
|
02/01/2023 |
- |
- |
- |
|
4 |
2 170 |
2 517.20 |
|
03/01/2023 |
- |
- |
- |
|
5 |
957 |
1 119.69 |
|
04/01/2023 |
1 |
1 000 |
1 140.00 |
|
1 |
1 |
1.18 |
|
06/01/2023 |
2 |
2 000 |
2 220.00 |
|
- |
- |
- |
|
09/01/2023 |
- |
- |
- |
|
1 |
1 |
1.14 |
|
10/01/2023 |
1 |
1 000 |
1 100.00 |
|
- |
- |
- |
|
11/01/2023 |
- |
- |
- |
|
6 |
2 000 |
2 220.00 |
|
12/01/2023 |
1 |
1 000 |
1 100.00 |
|
13 |
5 606 |
6 390.84 |
|
13/01/2023 |
1 |
1 000 |
1 120.00 |
|
3 |
938 |
1 069.32 |
|
16/01/2023 |
3 |
1 500 |
1 665.00 |
|
1 |
1 000 |
1 130.00 |
|
17/01/2023 |
1 |
1 000 |
1 100.00 |
|
- |
- |
- |
|
18/01/2023 |
4 |
2 000 |
2 200.00 |
|
1 |
2 000 |
2 240.00 |
|
19/01/2023 |
3 |
2 000 |
2 180.00 |
|
- |
- |
- |
|
20/01/2023 |
3 |
2 001 |
2 141.07 |
|
- |
- |
- |
|
23/01/2023 |
7 |
2 999 |
3 148.95 |
|
- |
- |
- |
|
25/01/2023 |
6 |
4 000 |
3 920.00 |
|
- |
- |
- |
|
26/01/2023 |
- |
- |
- |
|
2 |
2 005 |
2 005.00 |
|
27/01/2023 |
6 |
4 000 |
3 920.00 |
|
4 |
2 000 |
2 040.00 |
|
30/01/2023 |
2 |
1 500 |
1 485.00 |
|
- |
- |
- |
|
31/01/2023 |
1 |
500 |
495.00 |
|
- |
- |
- |
|
01/02/2023 |
1 |
1 000 |
990.00 |
|
- |
- |
- |
|
02/02/2023 |
2 |
1 500 |
1 470.00 |
|
- |
- |
- |
|
03/02/2023 |
1 |
1 000 |
960.00 |
|
- |
- |
- |
|
06/02/2023 |
3 |
1 500 |
1 410.00 |
|
- |
- |
- |
|
07/02/2023 |
1 |
1 000 |
930.00 |
|
- |
- |
- |
|
08/02/2023 |
1 |
500 |
460.00 |
|
- |
- |
- |
|
09/02/2023 |
2 |
1 000 |
900.00 |
|
- |
- |
- |
|
13/02/2023 |
- |
- |
- |
|
7 |
4 000 |
3 600.00 |
|
14/02/2023 |
1 |
1 000 |
890.00 |
|
- |
- |
- |
|
15/02/2023 |
1 |
1 000 |
880.00 |
|
- |
- |
- |
|
17/02/2023 |
1 |
500 |
430.00 |
|
1 |
100 |
87.00 |
|
20/02/2023 |
1 |
50 |
43.00 |
|
4 |
4 900 |
4 263.00 |
|
23/02/2023 |
1 |
50 |
42.50 |
|
- |
- |
- |
|
24/02/2023 |
2 |
1 020 |
846.60 |
|
- |
- |
- |
|
27/02/2023 |
5 |
1 900 |
1 558.00 |
|
- |
- |
- |
|
28/02/2023 |
1 |
500 |
400.00 |
|
4 |
2 000 |
1 640.00 |
|
01/03/2023 |
3 |
1 964 |
1 571.20 |
|
1 |
2 000 |
1 620.00 |
|
02/03/2023 |
2 |
1 000 |
800.00 |
|
- |
- |
- |
|
03/03/2023 |
- |
- |
- |
|
2 |
504 |
403.20 |
|
06/03/2023 |
1 |
1 000 |
790.00 |
|
- |
- |
- |
|
07/03/2023 |
2 |
1 500 |
1 185.00 |
|
- |
- |
- |
|
08/03/2023 |
4 |
1 500 |
1 185.00 |
|
- |
- |
- |
|
|
Buy Side |
|
Sell Side |
|
|
Number of
executions |
Number of
shares |
Traded volume in EUR |
|
Number of
executions |
Number of
shares |
Traded volume in EUR |
|
Total |
128 |
74 584 |
62 919.32 |
|
128 |
74 584 |
62 919.32 |
|
09/03/2023 |
2 |
1 000 |
780.00 |
|
- |
- |
- |
|
10/03/2023 |
2 |
500 |
380.00 |
|
- |
- |
- |
|
13/03/2023 |
1 |
500 |
375.00 |
|
- |
- |
- |
|
15/03/2023 |
1 |
500 |
350.00 |
|
- |
- |
- |
|
17/03/2023 |
1 |
300 |
198.00 |
|
- |
- |
- |
|
20/03/2023 |
1 |
200 |
128.00 |
|
1 |
77 |
50.82 |
|
21/03/2023 |
- |
- |
- |
|
1 |
123 |
81.18 |
|
29/03/2023 |
1 |
300 |
180.00 |
|
- |
- |
- |
|
14/04/2023 |
- |
- |
- |
|
25 |
12 800 |
10 368.00 |
|
17/04/2023 |
5 |
1 800 |
1 260.00 |
|
- |
- |
- |
|
18/04/2023 |
- |
- |
- |
|
3 |
600 |
438.00 |
|
19/04/2023 |
9 |
4 000 |
2 520.00 |
|
- |
- |
- |
|
20/04/2023 |
2 |
1 300 |
767.00 |
|
- |
- |
- |
|
21/04/2023 |
3 |
1 000 |
580.00 |
|
- |
- |
- |
|
25/04/2023 |
2 |
1 000 |
550.00 |
|
- |
- |
- |
|
26/04/2023 |
- |
- |
- |
|
9 |
4 200 |
2 688.00 |
|
02/05/2023 |
- |
- |
- |
|
2 |
500 |
325.00 |
|
04/05/2023 |
1 |
300 |
180.00 |
|
- |
- |
- |
|
09/05/2023 |
1 |
1 000 |
580.00 |
|
2 |
4 000 |
2 400.00 |
|
10/05/2023 |
3 |
2 500 |
1 475.00 |
|
- |
- |
- |
|
12/05/2023 |
1 |
1 000 |
590.00 |
|
3 |
2 000 |
1 200.00 |
|
15/05/2023 |
1 |
1 000 |
600.00 |
|
- |
- |
- |
|
16/05/2023 |
2 |
2 000 |
1 160.00 |
|
- |
- |
- |
|
17/05/2023 |
- |
- |
- |
|
4 |
2 000 |
1 180.00 |
|
25/05/2023 |
2 |
2 000 |
1 160.00 |
|
- |
- |
- |
|
29/05/2023 |
5 |
3 000 |
1 710.00 |
|
- |
- |
- |
|
01/06/2023 |
- |
- |
- |
|
1 |
500 |
290.00 |
|
06/06/2023 |
1 |
300 |
165.00 |
|
- |
- |
- |
|
20/06/2023 |
1 |
500 |
255.00 |
|
- |
- |
- |
|
21/06/2023 |
2 |
600 |
300.00 |
|
- |
- |
- |
|
About Nicox |
|
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost, for lowering intraocular
pressure in patients with open-angle glaucoma or ocular
hypertension. The company is also conducting research on NCX 1728,
a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal
conditions. NCX 4251, a novel, patented, ophthalmic suspension of
fluticasone propionate nanocrystals for topical ocular application
for dry eye disease, is being developed by Ocumension Therapeutics
in China under an exclusive license agreement and is available for
partnering elsewhere. Nicox generates revenue from VYZULTA® in
glaucoma, licensed exclusively worldwide to Bausch + Lomb, and
ZERVIATE® in allergic conjunctivitis, licensed in multiple
geographies, including to Eyevance Pharmaceuticals, LLC (a wholly
owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S.
and Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets.Nicox, headquartered in Sophia Antipolis,
France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX)
and is part of the CAC Healthcare index.For more information on
Nicox, its products or pipeline, please visit: www.nicox.com. |
|
Analyst coverage |
|
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceEdison Investment
Research Pooya
Hemami London,
UKH.C. Wainwright &
Co Yi
Chen New York,
U.S.Kepler
Cheuvreux Arsene
Guekam Paris,
France |
|
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
|
Contacts |
|
|
NicoxGavin SpencerExecutive Vice President, Chief
Business Officer& Head of Corporate Development T +33 (0)4 97
24 53 00communications@nicox.com |
|
|
Forward-Looking Statements |
|
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 2.7 of the ‘Rapport
Annuel 2022’ which is available on Nicox’s website
(www.nicox.com). |
|
Nicox SADrakkar 2 - Bât D2405 route des
Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24
53 99 |
- EN_KeplerHalfYearlyReportingJune 2023_20230711
Nicox (LSE:0RCQ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nicox (LSE:0RCQ)
Gráfica de Acción Histórica
De May 2023 a May 2024
